In This Section

Yael P. Mossé, MD
Yael P. Mossé
Co-Leader, Genes, Genomics, and Pediatric Disease Research Affinity Group

Dr. Mossé's research goal is to improve cure rates for the childhood cancer neuroblastoma by discovering the genetic basis of the disease and translating rational therapeutic opportunities to the clinic. She studies the contribution of DNA sequence variations and activation mutations of anaplastic lymphoma kinase (ALK) genes on the development and progression of both inherited and acquired forms of neuroblastoma.



Subscribe to be notified of changes or updates to this page.

4 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Education and Training

BA, Smith College (Literature), 1993

MD, Sackler School of Medicine, Tel Aviv, 1997

Fellowship, Children's Hospital of Philadelphia (Hematology/Oncology), 2003

Titles and Academic Titles

Co-Leader, Genes, Genomics, and Pediatric Disease Research Affinity Group

Attending Physician

Associate Professor of Pediatrics

Professional Memberships

American Society of Clinical Investigation, 2012

Professional Awards

Young Investigator Award, American Society of Clinical Oncology, 2003

Career Development Award, American Society of Clinical Oncology, 2004

Foerderer-Murray Award, Children's Hospital of Philadelphia, 2006

First Inaugural James B. Nachman Junior Faculty Award in Pediatric Oncology, American Society of Clinical Oncology, 2012

Leadership Development Program, American Society of Clinical Oncology, 2013

Publication Highlights

Sano R, Krytska K, Larmour CE, Raman P, Martinez D, Ligon GF, Lillquist JS, Cucchi U, Orsini P, Rizzi S, Pawel BR, Alvarado D, Mossé YP. An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. Sci Transl Med. 2019 Mar; 11(483). PubMed PMID: 30867324
Infarinato NR, Park JH, Krytska K, Ryles HT, Sano R, Szigety KM, Li Y, Zou HY, Lee NV, Smeal T, Lemmon MA, Mossé YP. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. Cancer Discov. 2016 Jan; 6(1):96-107. PubMed PMID: 26554404
Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014 Nov; 26(5):682-94. PubMed PMID: 25517749
Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, Cole K, Toporovskaya Y, Zhao H, Carpenter EL, Christensen JG, Maris JM, Lemmon MA, Mossé YP. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med. 2011 Nov; 3(108):108ra114. PubMed PMID: 22072639
Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008 Oct; 455(7215):930-5. PubMed PMID: 18724359

Links of Interest